Inactive Instrument

Quotient Limited

U4W0

JE00BNNSZY03

Quotient : MosaiQ abstract presented at the Dresden Symposium on Autoantibodies

September 11, 2023

We are excited to announce that our abstract, titled "Performance characteristics of a new, fully automated planar microarray immunoassay for the detection of autoantibodies against Centromere Protein B and correlations with autoimmune disease diagnosis" will be presented at the 2023 Dresden Symposium on Autoantibodies, in Germany.

The study demonstrated that the MosaiQ® Centromere Protein B Microarray provides a high level of concordance with other CE-marked assays for detecting Centromere Protein B autoantibodies, with high reproducibility and repeatability.

Would you like to know more about MosaiQ, our Autoimmune diagnostic solution? Meet us at the 2023 Dresden Symposium on Autoantibodies (https://www.gfid-ev.de/dsa.htm), booth 12.

Attachments

Original Link
Original Document
Permalink

Disclaimer

Quotient Ltd. published this content on 12 September 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 September 2023 10:17:14 UTC.

Latest news about Quotient Limited

Quotient Limited Appoints James Harman Gaudin to its Board of Directors	23-06-14	CI
Certain Ordinary Shares of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Certain Restricted Share Units of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Certain Options of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Certain Warrants of Quotient Limited are subject to a Lock-Up Agreement Ending on 23-SEP-2022.	22-09-22	CI
Transcript : Quotient Limited, Q4 2022 Earnings Call, Jun 24, 2022	22-06-24
Quotient Limited Provides Earnings Guidance for the Fiscal Year 2023	22-06-24	CI

Chart Quotient Limited

Duration

Period

More charts

Company Profile

Quotient Limited is a Switzerland-based diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market. It is engaged in developing MosaiQ, which is its technology platform. The Company develops, manufactures and commercializes the products, including antisera products, reagent red blood cells, whole blood controls and ancillary products. Additionally The Company develops, manufactures and sells conventional reagent products to original equipment manufacturers (OEMs).

Sector

Pharmaceuticals

More about the company